Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates a new investigational treatment regimen of three consecutive monthly
doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for
the first three months then two-monthly follow-up until 18 months in patients with visual
impairment due to diabetic macular oedema.The aim of the study is to determine if this
treatment regimen is effective and safe in these patients.